
Bellerophon Therapeutics BLPH
Quartalsbericht 2023-Q3
hinzugefügt 14.11.2023
Bellerophon Therapeutics Langfristiger Schuldenstrom 2011-2026 | BLPH
Langfristiger Schuldenstrom Jährlich Bellerophon Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 203 K | 752 K | 704 K | 658 K | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 752 K | 203 K | 579 K |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | ||
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
Adagene
ADAG
|
1.18 M | $ 2.83 | -2.75 % | $ 159 M | ||
|
Biogen
BIIB
|
86.4 M | $ 177.27 | 0.62 % | $ 25.8 B | ||
|
ANI Pharmaceuticals
ANIP
|
1.8 M | $ 81.19 | -0.98 % | $ 1.57 B | ||
|
Amgen
AMGN
|
107 M | $ 339.82 | -0.91 % | $ 182 B | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
BioNTech SE
BNTX
|
39.5 M | $ 114.47 | -1.97 % | $ 27.2 B | ||
|
Aytu BioScience
AYTU
|
137 K | $ 2.56 | -0.78 % | $ 16.1 M | ||
|
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.23 | -0.92 % | $ 7.77 B | ||
|
CASI Pharmaceuticals
CASI
|
1.06 M | $ 0.99 | - | $ 135 M | ||
|
Catalyst Biosciences
CBIO
|
210 K | $ 10.0 | -1.43 % | $ 658 M | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | ||
|
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | ||
|
Cerus Corporation
CERS
|
2.28 M | $ 2.3 | -1.08 % | $ 424 M | ||
|
Aptose Biosciences
APTO
|
428 K | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | ||
|
Cellectis S.A.
CLLS
|
8.38 M | $ 3.81 | -4.51 % | $ 116 M | ||
|
Brickell Biotech
BBI
|
49 K | - | -5.38 % | $ 6.06 M | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Beam Therapeutics
BEAM
|
13.5 M | $ 28.26 | -3.52 % | $ 2.33 B | ||
|
Ascendis Pharma A/S
ASND
|
14.2 M | $ 223.79 | -0.07 % | $ 5 B | ||
|
Athira Pharma
ATHA
|
414 K | - | - | $ 269 M | ||
|
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
7.29 M | $ 68.89 | -0.33 % | $ 9.21 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
402 K | $ 24.53 | -0.2 % | $ 2.91 B | ||
|
Cardiff Oncology
CRDF
|
710 K | $ 1.68 | 3.75 % | $ 80.1 M | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
11 M | - | -9.72 % | $ 5.89 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
5.38 M | - | -15.15 % | $ 60.3 M | ||
|
Berkeley Lights
BLI
|
3.29 M | - | -7.31 % | $ 87 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 4.03 | -1.71 % | $ 8.77 B | ||
|
Amneal Pharmaceuticals
AMRX
|
224 M | $ 13.77 | -2.45 % | $ 4.25 B | ||
|
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B |